International Cardio

International Cardio Corporation, founded in 2007 and based in Chaska, Minnesota, is dedicated to the research and development of high-intensity focused ultrasound (HIFU) solutions for the non-invasive treatment of peripheral artery disease. The company's core mission is to maximize patient safety while effectively managing therapeutic outcomes. Their flagship product, the HIFU Synthesizer™, is a pre-CE Mark medical device designed to image, target, and non-invasively ablate tissue with sub-millimeter precision.

Notable affiliated individuals include key researchers and developers in the field of medical ultrasound technology. International Cardio has achieved significant milestones in pre-clinical testing, demonstrating the efficacy and precision of their HIFU Synthesizer™. As a privately-held company, they have attracted interest from investors focused on innovative medical technologies. Overall, International Cardio's impact lies in advancing non-invasive treatment options for artery disease, potentially improving patient outcomes and reducing the need for more invasive surgical procedures.